The incidence of a K-RAS4B mutation in colorectal cancer is around 50%, in pancreatic tumors even up to 90%.1 Thus, K-RAS4B has attracted widespread attention in cancer drug development. This evidence concerns the gene KRAS and colorectal cancer.